Amicus Therapeutics and GlaxoSmithKline have revised their Fabry agreement under which Amicus obtains global rights to develop and commercialize the investigational pharmacological chaperone migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.   Amicus will have sole rights to the global drug development, regulatory and commercial activities for the next-generation Fabry ERT (migalastat HCl co-formulated with ERT), as well as migalastat HCl ...